Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Finland

Research and Innovation Action · Running

ENDOTARGET Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and novel therapeutic targets for Arthritis

Coordinator
Hus-Yhtyma, Finland
Runs
1 January 2023 to 31 December 2026
Status
Running
EU funding
€6.8m
Total cost
€6.8m
Partners
14 organisations in 8 countries
Type
Research and Innovation Action
Grant agreement
101095084

What the project is doing

In the project's own words, from its summary on CORDIS.

Rheumatic diseases (RDs) affect more than 4% of Europe's population and cause significant disability, pain, reduced lifespan and a very high economic burden. In this project, we will explore the role of chronic systemic inflammation caused by intestinal microbiota derived immunologically active compounds, as a driver in the transition from health to disease, with a special focus on three RDs; osteoarthritis (OA), rheumatoid arthritis (RA), and spondylarthritis (SpA).

We aim to explore the relationship between gut microbiota, intestinal permeability, and endotoxemia. We aim to understand their role as drivers of disease onset and disease activity in RA, SpA and OA, as well as targets of preventive and therapeutic approaches. We will study the events leading from health to disease onset by i) taking advantage of geographically diverse large cohorts of people with available blood and faeces samples, ii) search for novel risk biomarkers for RA, SpA, and OA by using high-throughput OMICS-based analyses iii) conducting targeted clinical studies, iv) performing in vitro mechanistic studies to explore the gut-joint axis using tissue explant cultures and organ-on-chip models v) conducting interventional proof of concept studies of diet, faecal transplantation in RA and SpA patients, vi) exploring in vitro new potential drugs or nutraceuticals to cope with endotoxemia effects on target tissues.

By combining all these results, machine learning and AI-informed rheumatic disease prediction tool will be developed for clinicians to help them identify patients with increased risk of developing the target diseases. It will thus assist in the choice of personalized blueprint intervention to reduce the risk of these diseases and disease activity in RA and SpA and to slow down the progression of OA.

Who is involved

OrganisationCityCountryRole
Hus-YhtymaHelsinkiFinlandCoordinator
Technische Universitaet WienWienAustriaParticipant
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandAssociatedpartner
Sib Swiss Institute of BioinformaticsGenfSwitzerlandAssociatedpartner
Nec Laboratories Europe GmbHHeidelbergGermanyParticipant
Steinbeis 2i GmbHStuttgartGermanyParticipant
Tartu UlikoolTartuEstoniaParticipant
Fundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De CompostelaSantiago De CompostelaSpainThird party
Servizo Galego De SaudeSantiago De CompostelaSpainParticipant
Helsingin YliopistoHelsinkiFinlandParticipant
Fondazione EbrisSalernoItalyParticipant
Nec Italia SpACinisello Balsamo (Mi)ItalyThird party
Universita Degli Studi Della Campania Luigi VanvitelliCasertaItalyParticipant
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI